Stock listing
NASDAQ:CGON CG Oncology, Inc. Stock
Home listing (NASDAQ) of CG Oncology, Inc.
Follow CG Oncology, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CGON
$79.47 USD -0.53 (-0.7%)
Close on Nov 20, 2026
- Day range
- $79.23 – $83.12 USDNov 20, 2026
- Volume
- 1.67M sharesNov 20, 2026
- Market cap
- $7.10B USDAt the close on Nov 20, 2026 · price × 89.32M shares outstanding
- 52-week range
- $37.01 – $93.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $87.07M USDMedian day 890,166 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CGON · Home | $79.47 USD | -0.53 (-0.7%) | 1,673,971 | $80.32 | $83.12 | $79.23 | $80.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGON · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $79.47 | -0.53 | -0.7% | $80.32 | $83.12 | $79.23 | 1,673,971 | |
| $80.00 | +1.06 | +1.3% | $79.07 | $82.08 | $77.35 | 1,792,746 | |
| $78.94 | -5.84 | -6.9% | $82.51 | $83.97 | $73.00 | 3,160,874 | |
| $84.78 | +10.38 | +14.0% | $92.00 | $93.95 | $78.27 | 9,881,332 | |
| $74.40 | +4.25 | +6.1% | $71.19 | $76.06 | $68.13 | 3,238,544 | |
| $70.15 | -2.46 | -3.4% | $72.21 | $72.96 | $67.43 | 1,277,579 | |
| $72.61 | -0.03 | 0.0% | $73.21 | $75.19 | $72.49 | 890,166 | |
| $72.64 | -2.10 | -2.8% | $73.84 | $74.95 | $71.26 | 821,216 | |
| $74.74 | -1.25 | -1.6% | $77.19 | $77.99 | $72.41 | 1,511,579 | |
| $75.99 | +11.19 | +17.3% | $66.49 | $80.00 | $66.46 | 3,661,704 | |
| $64.80 | -2.91 | -4.3% | $67.34 | $67.34 | $64.16 | 931,516 | |
| $67.71 | +3.65 | +5.7% | $66.10 | $67.87 | $63.16 | 1,304,790 | |
| $64.06 | +2.10 | +3.4% | $62.52 | $65.79 | $62.35 | 724,745 | |
| $61.96 | -2.72 | -4.2% | $64.18 | $64.68 | $61.01 | 1,279,526 | |
| $64.68 | +1.21 | +1.9% | $63.02 | $65.55 | $60.63 | 870,326 | |
| $63.47 | -0.49 | -0.8% | $64.28 | $65.59 | $63.08 | 782,614 | |
| $63.96 | +1.02 | +1.6% | $62.53 | $64.12 | $62.30 | 944,090 | |
| $62.94 | +1.38 | +2.2% | $61.46 | $64.13 | $59.96 | 709,340 | |
| $61.56 | -0.15 | -0.2% | $61.76 | $62.80 | $61.06 | 880,160 | |
| $61.71 | -0.83 | -1.3% | $62.36 | $62.36 | $59.86 | 1,064,552 | |
| $62.54 | +0.30 | +0.5% | $61.95 | $63.19 | $61.40 | 579,519 | |
| $62.24 | +0.31 | +0.5% | $62.43 | $63.57 | $61.27 | 530,138 | |
| $61.93 | +1.97 | +3.3% | $60.16 | $62.71 | $60.16 | 766,680 | |
| $59.96 | +0.11 | +0.2% | $60.44 | $61.25 | $59.22 | 1,215,168 | |
| $59.85 | -2.01 | -3.2% | $61.86 | $62.00 | $59.37 | 1,079,700 | |
| $61.86 | +0.02 | 0.0% | $62.70 | $63.24 | $60.96 | 1,186,400 | |
| $61.84 | -0.56 | -0.9% | $62.48 | $63.44 | $61.27 | 1,100,400 | |
| $62.40 | -0.73 | -1.2% | $61.92 | $63.85 | $61.52 | 1,188,600 | |
| $63.13 | -0.69 | -1.1% | $63.43 | $64.15 | $62.68 | 660,600 | |
| $63.82 | +0.56 | +0.9% | $62.97 | $65.18 | $62.88 | 516,500 | |
| $63.26 | +0.88 | +1.4% | $61.65 | $63.71 | $61.11 | 910,300 | |
| $62.38 | -1.26 | -2.0% | $62.68 | $63.64 | $61.90 | 621,800 | |
| $63.64 | -5.07 | -7.4% | $69.17 | $69.17 | $63.19 | 774,400 | |
| $68.71 | +1.33 | +2.0% | $67.60 | $68.95 | $65.71 | 788,400 | |
| $67.38 | -0.97 | -1.4% | $69.35 | $69.73 | $66.61 | 1,541,100 | |
| $68.35 | -2.54 | -3.6% | $70.38 | $71.27 | $68.32 | 984,900 | |
| $70.89 | +0.37 | +0.5% | $70.34 | $73.16 | $69.23 | 1,330,900 | |
| $70.52 | +0.91 | +1.3% | $69.56 | $70.68 | $68.26 | 1,035,400 | |
| $69.61 | +2.46 | +3.7% | $66.96 | $69.94 | $66.01 | 1,759,600 | |
| $67.15 | -1.61 | -2.3% | $69.32 | $70.05 | $66.76 | 1,177,500 | |
| $68.76 | -4.60 | -6.3% | $73.10 | $73.44 | $68.15 | 1,444,200 | |
| $73.36 | -4.38 | -5.6% | $76.87 | $77.79 | $71.86 | 830,900 | |
| $77.74 | -0.51 | -0.7% | $78.31 | $80.63 | $76.25 | 1,641,900 | |
| $78.25 | +3.63 | +4.9% | $75.74 | $78.47 | $74.22 | 1,114,900 | |
| $74.62 | -1.00 | -1.3% | $75.87 | $75.87 | $72.82 | 1,779,200 | |
| $75.62 | +1.50 | +2.0% | $75.00 | $76.50 | $74.43 | 894,300 | |
| $74.12 | +1.57 | +2.2% | $72.66 | $74.59 | $72.66 | 795,600 | |
| $72.55 | -1.24 | -1.7% | $74.13 | $74.13 | $72.48 | 1,037,300 | |
| $73.79 | +1.44 | +2.0% | $72.30 | $74.67 | $71.78 | 829,900 | |
| $72.35 | +0.35 | +0.5% | $72.82 | $75.00 | $71.53 | 759,800 | |
| $72.00 | +0.04 | +0.1% | $70.91 | $72.58 | $70.00 | 657,900 | |
| $71.96 | -1.44 | -2.0% | $73.04 | $74.85 | $70.90 | 707,900 | |
| $73.40 | -1.27 | -1.7% | $73.23 | $74.60 | $72.25 | 550,800 | |
| $74.67 | +0.34 | +0.5% | $73.02 | $74.88 | $72.87 | 282,500 | |
| $74.33 | -0.26 | -0.3% | $74.94 | $75.02 | $73.69 | 359,700 | |
| $74.59 | -1.27 | -1.7% | $76.84 | $79.23 | $73.89 | 663,900 | |
| $75.86 | +0.70 | +0.9% | $74.74 | $76.24 | $74.20 | 876,100 | |
| $75.16 | +0.82 | +1.1% | $74.09 | $76.14 | $72.12 | 840,700 | |
| $74.34 | -4.67 | -5.9% | $78.15 | $78.16 | $73.93 | 612,600 | |
| $79.01 | +0.59 | +0.8% | $78.01 | $79.40 | $77.63 | 328,900 | |
| $78.42 | -0.53 | -0.7% | $78.29 | $78.94 | $76.87 | 507,800 | |
| $78.95 | +0.72 | +0.9% | $79.00 | $80.07 | $78.10 | 736,169 | |
| $78.23 | -1.58 | -2.0% | $79.44 | $79.89 | $77.51 | 1,162,618 | |
| $79.81 | +2.20 | +2.8% | $78.69 | $79.89 | $77.38 | 701,700 | |
| $77.61 | -3.07 | -3.8% | $79.50 | $79.71 | $77.17 | 668,000 |
- Ticker
- NASDAQ:CGON
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 6, 2026
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · Nov 16, 2026
Investor Presentation (November 2026)
Investor deck · 31 slides
Latest news
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 6, 2026
Closed $75.99 (+17.3%) on Nov 6, 2026
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Oct 13, 2026
Closed $62.40 (-1.2%) on Oct 13, 2026
CG Oncology to Present at Upcoming Investor Conferences in September
Sep 2, 2026
Closed $74.59 (-1.7%) on Sep 2, 2026
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 6, 2026
Closed $74.85 (+3.4%) on Aug 6, 2026
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Jul 27, 2026
Closed $72.62 (-1.2%) on Jul 28, 2026
CG Oncology to Present at Upcoming Investor Conferences in June
May 28, 2026
Closed $62.29 (+2.6%) on May 29, 2026
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 19, 2026
Closed $63.30 (+0.6%) on May 19, 2026
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 15, 2026
Closed $66.93 (-3.7%) on May 15, 2026
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
May 11, 2026
Closed $72.07 (+4.0%) on May 12, 2026
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026
Closed $69.62 (+0.6%) on May 8, 2026
CG Oncology, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 60 in all · newest Nov 6, 2026 · oldest 2024
- Decks
- 31 decks · latest Nov 16, 2026
Where CG Oncology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CGON · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CGON | BOATS | United States | USD |
Valuation
EV/sales 992× against a median of 13.5×: the highest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.12B USD
- P/E
- Loss
- EV/sales
- 992×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 7.2×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.83
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Summit Therapeutics Inc. · NASDAQ:SMMT | US$7.96B | US$7.33B | n/a | n/a | n/a | 14.1× | n/a | 0.0× | 1.91 |
| Protagonist Therapeutics, Inc. · NASDAQ:PTGX | US$7.92B | US$7.13B | 23.1× | 12.9× | 22.0× | 7.3× | 62.0% | 0.0× | 0.93 |
| Alkermes plc · NASDAQ:ALKS | US$7.55B | US$8.31B | n/a | 4.7× | 57.3× | 4.0× | −0.0% | 0.8× | 0.80 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Median of the others | US$6.73B | US$6.34B | 23.1× | 13.5× | 39.6× | 8.7× | −27.3% | 0.3× | 1.30 |
Forecasts
9 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 92.15 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.93 · 10 analysts
- Revenue, year to Dec 2026
- 4.69M · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Arthur Kuan | Chairman, President & Chief Executive Officer |
| Jim DeTore | Chief Financial Officer |
| Josh Patterson | General Counsel & Chief Compliance Officer |
| Megan Knight | Investor Relations |
| Sarah Connors | Vice President, Communications and Patient Advocacy |
| Brian Liu | Managing Director, Longitude Capital |
| Christina Rossi | Biopharmaceutical Executive & Board Member |
| Isabel Kalofonos | Chief Commercial Officer |
| Jim Mulé | Director of Cell-based Therapies, Moffitt Cancer Center |
| Leonard Post | Chief Scientific Officer, Vivace Therapeutics |
| Swapnil Bhargava | Chief Technical Officer |
| Victor Tong | Managing Director, Decheng Capital |
| Vijay Kasturi | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Arthur Kuan | Chairman, President & Chief Executive Officer |
| Christina Rossi | Biopharmaceutical Executive & Board Member |
| Leonard Post | Chief Scientific Officer, Vivace Therapeutics |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · Before open | +17.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +3.4% |
| Q1 2026 | May 8, 2026 · Before open | +0.6% |
| Q4 2025 | Mar 27, 2026 | −4.1% |
| Q3 2025 | Nov 14, 2025 · Before open | +8.6% |
| Q2 2025 | Aug 8, 2025 · Before open | +2.0% |
| Q1 2025 | May 13, 2025 · Before open | −3.9% |
| Q4 2024 | Mar 28, 2025 | −9.1% |
| Q3 2024 | Nov 12, 2024 · Before open | −6.8% |
| Q2 2024 | Aug 8, 2024 · Before open | +7.0% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −7.4% |
| Q4 2023 | Mar 26, 2024 · Before open | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 31 slides | Nov 16, 2026 |
| New England Section of the American Urological Association Annual Meeting 2026 | Conference | 8 slides | Oct 24, 2026 |
| New England Section of the American Urological Association Annual Meeting 2026 | Conference | 12 slides | Oct 23, 2026 |
| SUO Annual Meeting at AUA 2026 | Conference | 15 slides | May 16, 2026 |
| EAU Annual Meeting (EAU26) 2026 | Conference | 8 slides | Mar 16, 2026 |
| Investor Presentation (January 2026) | Investor deck | 28 slides | Jan 9, 2026 |
| Investor Presentation (2026) | Investor deck | 30 slides | 2026 |
| SUO Annual Meeting (SUO25) 2025 | Conference | 13 slides | Dec 5, 2025 |
| EAU 2025 | Conference | 7 slides | November 2025 |
| Technical Presentation (November 2025) | Technical | 7 slides | November 2025 |
All 31 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2025) | Technical | 7 slides | November 2025 |
| NCSAUA 2025 | Conference | 12 slides | Oct 16, 2025 |
| Technical Presentation (October 2025) | Technical | 14 slides | Oct 16, 2025 |
| NCSAUA 2025 | Conference | 12 slides | Oct 16, 2025 |
| NCSAUA Annual Meeting 2025 | Conference | 11 slides | Oct 16, 2025 |
| Investor Presentation (September 2025) | Investor deck | 31 slides | Sep 9, 2025 |
| Technical Presentation (September 2025) | Technical | 14 slides | Sep 6, 2025 |
| ASCO Annual Meeting 2025 | Conference | 9 slides | Jun 2, 2025 |
| AUA Annual Meeting 2025 | Conference | 14 slides | Apr 26, 2025 |
| Technical Presentation (April 2025) | Technical | 13 slides | Apr 25, 2025 |
| 40th Annual EAU Congress (EAU25) (March 2025) | Conference | 14 slides | Mar 24, 2025 |
| Technical Presentation (March 2025) | Technical | 12 slides | Mar 12, 2025 |
| ASCO Annual Meeting 2024 | Conference | 13 slides | Jun 2, 2024 |
| Investor Presentation (June 2024) | Investor deck | 28 slides | June 2024 |
| AUA Annual Meeting 2024 | Conference | 16 slides | May 5, 2024 |
| AUA Annual Meeting 2024 | Conference | 17 slides | May 3, 2024 |
| Investor Presentation (January 2024) | Investor deck | 26 slides | January 2024 |
| Technical Presentation (2024) | Technical | 14 slides | 2024 |
| ASCO Genitourinary Cancers Symposium 2024 | Conference | 8 slides | 2024 |
| SUO Annual Meeting 2023 | Conference | 15 slides | Dec 1, 2023 |
| AUA 2023 Annual Meeting | Conference | 12 slides | 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$238M raised · US$28 a share · Morgan Stanley & Co. LLC +4 Dealers: Morgan Stanley & Co. LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), LifeSci Capital LLC | Dec 16, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Jan 24, 2024.
- Price
- US$19.00 a share
- Shares offered
- 20,000,000 shares of common stock
- Offering size
- US$380 million
- Underwriters' option
- Up to 3,000,000 more shares
- Underwriters
- Morgan Stanley, Goldman Sachs & Co. LLC, Cantor, LifeSci Capital · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 27, 2023 |
| Filed publicly | Jan 2, 2024 |
| Amended twice | Newest Jan 23, 2024 |
| Shares registered with an exchange | Jan 22, 2024 |
| Declared effective by the SEC | Jan 24, 2024 |
| Final prospectus, with the price | Jan 25, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 25, 2024 |
| EFFECT · Notice that a registration is effective | Jan 24, 2024 |
| S-1MEF · Registration of more shares for the same offering | Jan 24, 2024 |
| CERT · Exchange's certificate of listing | Jan 24, 2024 |
| S-1/A · Registration statement, amended | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 22, 2024 |
| CORRESP · Letter to the SEC | Jan 22, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 22, 2024 |
| S-1/A · Registration statement, amended | Jan 18, 2024 |
| CORRESP · Letter to the SEC | Jan 5, 2024 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 2, 2024 |
| S-1 · Registration statement | Jan 2, 2024 |
| UPLOAD · Letter from the SEC | Dec 18, 2023 |
| DRSLTR · Letter to the SEC with a draft | Dec 4, 2023 |
| DRS/A · Draft registration statement, amended | Dec 4, 2023 |
| UPLOAD · Letter from the SEC | Nov 27, 2023 |
| DRS · Draft registration statement | Oct 27, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 25, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 4.04M | 1.14M | 204.0K |
| Research and development | 116.6M | 82.1M | 45.8M |
| Operating income | -190.8M | -114.7M | -55.4M |
| Depreciation and amortization | 1.45M | 32.0K | 17.0K |
| EBITDA | -189.3M | -114.6M | -55.4M |
| Income tax | -270.0K | 1.00K | 1.00K |
| Net income | -161.0M | -88.0M | -48.6M |
| Earnings per share, basic | -2.08 | -1.41 | -15.65 |
| Earnings per share, diluted | -2.08 | -1.41 | -15.65 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 32.5M | 257.1M | 8.27M |
| Short-term investments | 709.7M | 484.9M | 179.4M |
| Receivables | 688.0K | 0 | |
| Inventory | 1.56M | 0 | |
| Current assets | 759.5M | 754.2M | 194.1M |
| Property, plant and equipment | 15.6M | 272.0K | 69.0K |
| Goodwill | 10.3M | 0 | |
| Total assets | 791.6M | 754.8M | 199.3M |
| Accounts payable | 5.71M | 6.52M | 3.24M |
| Current liabilities | 30.8M | 21.4M | 14.3M |
| Long-term debt | 3.00M | 0 | |
| Total debt | 3.00M | 0 | |
| Total liabilities | 39.0M | 21.4M | 14.5M |
| Shareholders' equity | 752.6M | 733.4M | -123.1M |
| Shares outstanding | 80.7M | 76.2M | 5.22M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -132.3M | -78.7M | -45.7M |
| Capital spending | -134.0K | -234.0K | |
| Free cash flow | -132.5M | -78.9M | |
| Cash from investing | -245.8M | -300.8M | -121.2M |
| Cash from financing | 153.6M | 628.3M | 87.0M |
| Change in cash | -224.6M | 248.8M | -79.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 28, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 26, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 13, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2026 | Results | SEC |
| 8-K · Current report | Jan 13, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 26, 2025 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Aug 6, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 17, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Mar 28, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Dec 13, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 13, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 11, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 11, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 6, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 5, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Nov 14, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Jul 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 16, 2024 | Insider trade | SEC |
This page holds 200 of 249 filings. Open Filings
Cap table
Built by 6ix from CG Oncology, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 89,318,916
- Fully diluted
- 89,318,916
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 89,318,916 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 89,318,916 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christina Rossi Other companies: Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021); Blueprint Medicines Corp (Chief Operating Officer · Since at least Oct 29, 2018) | Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025 |
| Corleen Roche Other companies: Iovance Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 15, 2025); Immunome, Inc. (Chief Financial Officer · Apr 19, 2021 – Jun 8, 2023 · Past) | CFO · Jan 24, 2024 – Apr 15, 2025 · Past |
| Isabel Kalofonos Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Dec 16, 2024); ImmunoGen Inc (SVP & CHIEF COMMERCIAL OFFICER · Apr 24, 2023 – Feb 12, 2024 · Past) | Chief Commercial Officer · Since at least Oct 13, 2026 |
| Jim DeTore Other companies: Kineta Inc. (See Remarks · Aug 4, 2016 – Aug 4, 2016 · Past); Bluebird bio Inc (Chief Financial Officer · Nov 10, 2014 – Dec 1, 2014 · Past) | Chief Financial Officer · Since at least Nov 17, 2025 |
| Josh Patterson Other companies: Gamida Cell Ltd (GENERAL COUNSEL · Jan 1, 2022 – Jan 31, 2024 · Past); Akcea Therapeutics Inc (General Counsel · Mar 6, 2020 – Oct 12, 2020 · Past) | See Remarks · Since at least May 13, 2024 |
| Susan E. Graf Other companies: Aardvark Therapeutics, Inc. (Board Member · Since at least Feb 12, 2025); Epizyme Inc (Chief Business Officer · Apr 25, 2016 – Feb 9, 2018 · Past) | Director · Since at least Jan 24, 2024 |
| James Mulay Other companies: Fulgent Genetics, Inc. (Director · May 30, 2019 – May 30, 2019 · Past) | Director · Since at least Jan 24, 2024 |
| John McAdory Other companies: Oncolytics Biotech Inc. (Chief Operating Officer · Since at least Jun 2, 2026) | EVP of Strategy and Operations · Jan 14, 2026 – Nov 5, 2026 · Past |
| Victor Edward Tong Jr Other companies: Aardvark Therapeutics, Inc. (Director · Since at least Feb 12, 2025) | Director · Since at least Jan 24, 2024 |
| Victor Tong Other companies: Aardvark Therapeutics, Inc. (Managing Director · Since at least Nov 5, 2026) | Managing Director, Decheng Capital · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Ambaw Bellete | President and COO · Since at least Apr 15, 2025 |
| Arthur Kuan | Chairman, President & Chief Executive Officer · Since at least Jan 24, 2024 |
| Brian Liu | Managing Director, Longitude Capital · Since at least Jan 24, 2024 |
| Hong Fang Song | Director · Since at least Jan 24, 2024 |
| Jim Mulé | Director of Cell-based Therapies, Moffitt Cancer Center · Since at least Nov 5, 2026 |
| Leonard Post | Chief Scientific Officer, Vivace Therapeutics · Since at least Oct 19, 2026 |
| Megan Knight | Investor Relations · Since at least Sep 2, 2026 |
| Sarah Connors | Vice President, Communications and Patient Advocacy · Since at least Sep 2, 2026 |
| Swapnil Bhargava | Chief Technical Officer · Since at least Nov 5, 2026 |
| Vijay Kasturi | Chief Medical Officer · Since at least Jan 24, 2024 |
Log in to ask 6ix AI your own questions about CG Oncology, Inc.